Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 24, Pages 2596-2604Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v24.i24.2596
Keywords
Hepatocellular carcinoma; MicroRNAs; Serum; Biomarker; Diagnosis
Categories
Funding
- National Key R&D Program of China [2016YFC0106604]
- National Natural Science Foundation of China [81502591]
Ask authors/readers for more resources
AIM To determine a panel of serum microRNAs (miRNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma (HCC). METHODS We initially screened 9 out of 754 serum miRNAs by TaqMan Low Density Array in two pooled samples respectively from 35 HCC and 35 normal controls, and then validated individually by RT-qPCR in another 114 patients and 114 controls arranged in two phases. The changes of the selected miRNAs after operation and their prognostic value were examined. RESULTS miR-375, miR-10a, miR-122 and miR-423 were found to be significantly higher in HCC than in controls (P < 0.0001), and the area under the receiver-operating-characteristic curve for the 4-miRNA panel was 0.995 (95%CI: 0.985-1). All the four miRNAs were significantly reduced after surgical removal of the tumors (P < 0.0001), while still higher than normal controls (at least P < 0.05) CONCLUSION The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available